

Product datasheet for TL309645

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436

OriGene Technologies, Inc.

Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

SART3 Human shRNA Plasmid Kit (Locus ID 9733)

Product data:

Product Type: shRNA Plasmids

Product Name: SART3 Human shRNA Plasmid Kit (Locus ID 9733)

Locus ID: 9733

Synonyms: DSAP1; P100; p110; p110(nrb); RP11-13G14; TIP110

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: SART3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 9733).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: BC015627, NM 014706, NM 014706.1, NM 014706.2, NM 014706.3, BC093784, BC004547,

BC024279, BC032601, BC041638, BC103706, BC111983, BC143253

UniProt ID: 015020

Summary: The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection

antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be

involved in the regulation of mRNA splicing. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).